Sep. 30, 2013 — Cystic fibrosis is a lethal genetic disorder that in France affects one child per 4,500 births. An international team led by scientists at the Institut Fédératif de Recherche Necker-Enfants Malades (CNRS/Inserm/Université Paris Descartes), led by Aleksander Edelman, has recently discovered two new compounds that could be used to treat patients carrying the most common mutation. Continue reading New Compounds Display Strong Therapeutic Potential for Cystic Fibrosis
Science/AAAS | News
Fatal weakness. Pathogens such as methicillin-resistant Staphylococcus aureus (above) develop vulnerabilities as they evolve resistance to antibiotics. Choosing antibiotics that exploit these weaknesses can thwart resistant bacteria. Continue reading If Chosen Wisely, Existing Drugs Fight Resistant Bugs
US-based clinical stage drug discovery and development firm Celtaxsys has completed Phase I clinical trial of its drug CTX-4430 to treat patients with cystic fibrosis (CF) lung disease.
Celtaxsys Aus, the company’s Australian subsidiary, has carried out the first of two clinical trials in Continue reading Celtaxsys completes Phase I trial of cystic fibrosis drug
Local researchers are working to advance stem cell research that will allow scientists to grow organs.
By Jenni Whalen
Researchers from the Center for Regenerative Medicine, which is a collaboration of Boston Medical Center and Boston University scientists, are working to advance stem cell research in a way that will allow them to grow organs, including lungs, in the not-too-distant future. Continue reading Growing Lungs May Soon Be A Reality
Of the over 1,900 errors already reported in the gene responsible for cystic fibrosis (CF), it is unclear how many of them actually contribute to the inherited disease. Now a team of researchers reports significant headway in figuring out which mutations are benign and which are deleterious. Continue reading Scientists pinpoint 105 additional genetic errors that cause cystic fibrosis
The bacterium Pseudomonas aeruginosa needs iron to establish and maintain a biofilm in the lungs of cystic fibrosis patients, and therapies have been proposed to deprive the bacteria of this necessary element. However, these techniques may not work, according to a new study published in Continue reading Two forms of iron must be targeted to control cystic fibrosis lung infection
CARY, N.C., July 29, 2013 – Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today it is now actively marketing PERTZYE® (pancrelipase) in the U.S. for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis. PERTZYE is the only U.S. Food and Drug Administration (FDA) approved pancreatic enzyme replacement therapy (PERT) containing Continue reading Cornerstone Therapeutics Initiates PERTZYE® (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
Vertex’s strategy in cystic fibrosis (CF) is to provide benefit to as many CF patients as possible, and to maximize the benefit for these patients, with our approved and investigational medicines. Continue reading Vertex Updates Recent Progress and Upcoming Milestones in Clinical Development Programs
Experts believe a pioneering breakthrough by a Manchester hospital research team could pave the way for doctors to better understand and treat adults with Cystic Fibrosis (CF), helping them live longer and healthier lives. http://www.medicalnewstoday.com/releases/262897.php Continue reading Manchester Researchers Discover Half Of All Adults With Cystic Fibrosis Affected By Airborne Fungus
The latest cystic fibrosis research summarized by the study authors. No spin, no headlines. More added daily. cfunite.org/research
The next live CFUnite event, with added opportunities for interaction, will discuss the genes and genetics of cystic fibrosis. What does dF508, G551D and all the other numbers actually mean? Continue reading Cystic Fibrosis Genes & Gene Therapy–June 29th 13:00 (BST)